The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Frailty IO: Frailty parameters and incidence of immune related adverse events in older patients treated with immune checkpoint blockers (ICB).
 
Capucine Baldini
Consulting or Advisory Role - Bicycle Therapeutics; Janssen Oncology; Rising Tide Foundation
Research Funding - Foundation BMS (Inst)
Expert Testimony - Abbvie; Bristol-Myers Squibb
Travel, Accommodations, Expenses - Amgen; MSD Oncology; Roche/Genentech
 
Bérengère Beauplet
No Relationships to Disclose
 
Lauren Seknazi
No Relationships to Disclose
 
Arnaud Pages
No Relationships to Disclose
 
Marie Vanneste
No Relationships to Disclose
 
Sandrine Estivin
No Relationships to Disclose
 
Nicolas Saint Alme
No Relationships to Disclose
 
Vincent Goldschmidt
Travel, Accommodations, Expenses - MSD
Other Relationship - Abbvie (Inst); Adaptimmune (Inst); Adlai Nortye (Inst); Aduro Biotech (Inst); Agios (Inst); Amgen (Inst); AstraZeneca (Inst); AVEO (Inst); Basilea Pharmaceutical (Inst); Bayer HealthCare Pharmacuticals (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Boston Pharmaceuticals (Inst); Bristol Myers Squibb Foundation (Inst); CASI Pharmaceuticals (Inst); Cato Research (Inst); CellCentric (Inst); Cellgen (Inst); Chugai Pharma (Inst); Cullinan Oncology (Inst); Daiichi Sankyo Europe GmbH (Inst); Debiopharm Group (Inst); Eisai (Inst); EverImmune (Inst); Exelixis (Inst); Faron Pharmaceuticals (Inst); Foghorn Therapeutics (Inst); FORMA Therapeutics (Inst); GamaMabs Pharma (Inst); Genentech (Inst); Genmab (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); IgM Biosciences (Inst); ImCheck therapeutics (Inst); Incyte (Inst); Innate Pharma (Inst); Iris International (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Janssen Oncology (Inst); Janssen Research & Development (Inst); K-Group Beta (Inst); Kinnate Biopharma (Inst); Kura Oncology (Inst); Kyowa Kirin International (Inst); La Roche-Posay (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Menarini (Inst); SERVIER (Inst)
 
Maxime Frelaut
No Relationships to Disclose
 
Aymeric Kisserli
No Relationships to Disclose
 
Sarah Guitteny
No Relationships to Disclose
 
Celine Nagera Lazarovici
No Relationships to Disclose
 
Rachid Mahmoudi
No Relationships to Disclose
 
Coline Montegut
No Relationships to Disclose
 
Julieta Rodriguez
No Relationships to Disclose
 
Anne-Laure Couderc
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Ferring; Nutricia; Sanofi
 
Elena Paillaud
Honoraria - GlaxoSmithKline; LEO Pharma; MSD; NOVARTIS; Pfizer
Research Funding - Pfizer
 
Florence Canoui-Poitrine
No Relationships to Disclose